"We are committed to an investment upwards of USD 75 million, (approximately Rs 600 crore) to upgrade and enhance existing facilities at th...

Hetero is the first biopharmaceutical company in India to receive manufacturing & marketing (M&M) approval for the product manufactured loc...

Under the licensing deal, Hetero will be allowed to expand access of Molnupiravir in India and in other low-and middle-income countries, fo...

In an interaction with the Russian president Vladimir Putin on Friday through a video conference, Hetero group’s Chairman Dr Bandi Parthasa...

If successful, Hetero will become the first Indian drug maker to introduce favipiravir in injection form which is hitherto available only i...

"The launch of 'Favivir 800/200' is aimed at enhancing patients' adherence to treatment regimen by reducing the number of pills they are re...

This is the second drug developed by Hetero after Covifor, the generic version of Remdesivir injection to be administered intravenously in ...

The Hyderabad-headquartered Hetero said it will dispatch second batch of 10,000 vials of the generic drug in the injectable form (100mg via...

Hetero will produce and launch the first generic Remdesivir under Covifor brand in India following positive clinical outcomes under a licen...

The product will be marketed by Hetero Healthcare under the brand name ‘MaburaTM’ in India, the company said.

The company "has received the approval for the generic version of 'Sofosbuvir+Velpatasvir' combination from the Drugs Controller General of...

Cipla said the group, through its subsidiary Camber Pharmaceuticals Inc., will continue to strengthen its operations in the US.

People close to the transaction said Cipla will buy Invagen and Camber, Hetero’s wholly owned subsidiary, for about $550 million.

Hetero has launched biosimilar Rituximab in India used for treatment of certain types of cancers and rheumatoid arthritis under the brand n...

Hetero has dedicated manufacturing facilities at Visakhapatnam in Andhra Pradesh and Baddi in Himachal Pradesh exclusively to produce the d...

The first phase of the collaboration will be distribution of Hetero's medicines in the UAE, Chairman of Hetero Group B P S Reddy said.

Hyderabad based Hetero labs through an agreement with Geneva based Medicines Patent Pool will produce four key HIV drugs developed by Gilea...